Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab

BACKGROUND: We hypothesized that elevations of plasma Oncostatin M (OSM) would be associated with infliximab nonresponse. METHODS: Plasma OSM was measured in Crohn disease patients pre-infliximab with biochemical response (>50% reduction in fecal calprotectin) as the primary outcome. RESULTS: The...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Crohns Colitis 360
Hoofdauteurs: Minar, Phillip, Lehn, Christina, Tsai, Yi-Ting, Jackson, Kimberly, Rosen, Michael J, Denson, Lee A
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2019
Onderwerpen:
Observations And Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6798793/
https://ncbi.nlm.nih.gov/pubmed/31667468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/crocol/otz026
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items